Titan Nutrition CO
HELIXIR PHARMACEUTICALS - TIRZEPATIDE (GLP-1) 5mg
HELIXIR PHARMACEUTICALS - TIRZEPATIDE (GLP-1) 5mg
Couldn't load pickup availability
Advanced Dual-Receptor Agonist for Metabolic Control & Body Recomposition
Dual GLP-1/GIP agonist for advanced metabolic control. It acts on two hormonal pathways simultaneously: optimizes insulin response, reduces appetite in a sustained way and promotes fat loss.
✓ Dual appetite control and sustained satiety signaling
✓ Significant improvement in insulin sensitivity
✓ Progressive fat loss with muscle mass preservation
✓ Optimization of the metabolic profile in structured protocols
✓ Weight management support with nutritional discipline
MAIN ACTION
It activates the GLP-1 and GIP receptors simultaneously, enhancing the satiety signals, improving insulin sensitivity and favoring the oxidation of fatty acids as a primary energy source in structured protocols.
RESULTS IN RESEARCH
QUALITY AND ORIGIN
Purity greater than 99%, verified by HPLC analysis. Synthesized under pharmaceutical standards in US laboratories. USA
FACT SHEET
MOLECULAR STRUCTURE
Sequence: Synthetic peptide of 39 amino acids
Molecular weight: ~4813 Da
PHARMACOKINETICS
Half life: ~5 days
Bioavailability: High (subcutaneous)
Metabolism: Degradation by enzymatic proteases
Elimination: Mainly renal and fecal
USE AND ADMINISTRATION (RESEARCH)
Route: Subcutaneous (injection)
Dose under study: 2.5, 5, 7.5, 10, 12.5, 15 mg according to protocol
Frequency: 1 time per week
Presentation: 5 mg freeze-dried bottle — reconstitute with bacteriostatic water before use
MECHANISM OF ACTION IN KEY SYSTEMS
Brain
Increases satiety and reduces appetite.
Pancreas
Increases insulin secretion and reduces glucose-dependent glucagon.
Stomach
Delays gastric emptying.
Liver
Improves insulin sensitivity and reduces hepatic glucose production.
Adipose tissue
Reduces fat mass and improves lipid metabolism.
Muscle
Increases glucose capture and improves energy metabolism.
AREAS OF APPLICATION IN RESEARCH
✓ Type 2 diabetes✓ Chronic weight management in adults with obesity or overweight
✓ Metabolic syndrome
✓ Non-alcoholic steatohepatitis (NASH) in investigation
✓ Cardiovascular prevention in high-risk patients
WARNINGS AND SECURITY
⚠ Common adverse events: nausea, vomiting, constipation, abdominal pain.⚠ Risk of pancreatitis (rare).
⚠ Do not use in patients with a history of medullary thyroid carcinoma (MTC) or MEN syndrome 2.
⚠ Do not use during pregnancy or lactation.
Share
